CRISPR Startups Give Genome Editing Several New Twists
By Catherine Shaffer,
Genetic Engineering & Biotechnology News
| 08. 03. 2020
Base editors, exonucleases, and other refinements enable advances in pathogen recognition, antibacterial development, genetic medicine, xenotransplantation, and agriculture
Just seven years ago, the Broad Institute’s Feng Zhang, PhD, and Harvard geneticist George Church, PhD, separately demonstrated that in human cell cultures, genome editing could be performed using a CRISPR system. CRISPR, which stands for clustered regularly interspaced short palindromic repeats, first came to light as part of a naturally occurring defense system in bacteria. CRISPR DNA in bacteria includes repetitive elements and spacer elements, the latter of which encode RNA molecules that complex with a CRISPR-associated (Cas) nuclease and guide it to viral targets, that is, viruses that possess genetic material complementary to guide RNA.
After Zhang and Church showed that CRISPR-Cas9, one of the crude adaptive immune systems found in bacteria, had potential as a genomic engineering tool, many developers followed their lead. Early CRISPR startups—such as Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics—went public and have since prospered. And now a new crop of startups is showing that there’s still plenty of room for innovation.
Each of the new CRISPR startups features a unique twist on the original CRISPR formula. Examples of CRISPR twists include exotic...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...